TCGA-OL-A6VO-01A-12R-A33J-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 29
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.630
- MYC_TARGETS_V2+0.630
- MYC_TARGETS_V1+0.530
- G2M_CHECKPOINT+0.500
- INTERFERON_ALPHA_RESPONSE+0.480
- DNA_REPAIR+0.320
- INTERFERON_GAMMA_RESPONSE+0.320
- SPERMATOGENESIS+0.280
- MTORC1_SIGNALING+0.260
- OXIDATIVE_PHOSPHORYLATION+0.240
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.520
- ANGIOGENESIS-0.460
- TGF_BETA_SIGNALING-0.400
- ESTROGEN_RESPONSE_EARLY-0.380
- APICAL_SURFACE-0.350
- UV_RESPONSE_DN-0.330
- MYOGENESIS-0.320
- PROTEIN_SECRETION-0.290
- COAGULATION-0.270
- ESTROGEN_RESPONSE_LATE-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AR-A0TU-01A-31R-A109-07 | — | E | 0.921 |
| 2 | 20130067.TNBC | — | E | 0.902 |
| 3 | SRR8518219 | — | E | 0.894 |
| 4 | TCGA-E2-A14N-01A-31R-A137-07 | — | E | 0.886 |
| 5 | SRR8518323 | — | E | 0.885 |
| 6 | TCGA-E2-A14R-01A-11R-A115-07 | — | E | 0.879 |
| 7 | TCGA-E9-A22G-01A-11R-A157-07 | — | E | 0.872 |
| 8 | SRR8518289 | — | E | 0.861 |
| 9 | SRR8518297 | — | E | 0.861 |
| 10 | 20020093.Her2HRneg | — | E | 0.856 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.630 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.630 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.530 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.480 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.320 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.320 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.280 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.260 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.240 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.230 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.140 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.130 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.110 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.090 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.080 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.080 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.070 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.050 | Inavolisib | — uncovered |